Insider Transactions in Q1 2024 at Agios Pharmaceuticals, Inc. (AGIO)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 07
2024
|
Kaye I Foster Cheek Director |
SELL
Open market or private sale
|
Direct |
1,285
-18.87%
|
$39,835
$31.62 P/Share
|
|
Mar 06
2024
|
Kaye I Foster Cheek Director |
SELL
Open market or private sale
|
Direct |
4,415
-39.34%
|
$136,865
$31.99 P/Share
|
|
Mar 05
2024
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,127
-21.33%
|
$100,064
$32.3 P/Share
|
|
Mar 05
2024
|
Kaye I Foster Cheek Director |
SELL
Open market or private sale
|
Direct |
300
-2.6%
|
$9,600
$32.21 P/Share
|
|
Mar 05
2024
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,642
-3.38%
|
$84,544
$32.57 P/Share
|
|
Mar 05
2024
|
Cecilia Jones Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
672
-4.33%
|
$21,504
$32.57 P/Share
|
|
Mar 05
2024
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,156
-7.17%
|
$132,992
$32.57 P/Share
|
|
Mar 05
2024
|
James William Burns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,642
-3.56%
|
$84,544
$32.57 P/Share
|
|
Mar 01
2024
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,834
+9.12%
|
-
|
|
Mar 01
2024
|
Theodore James Washburn Jr. Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,127
+23.31%
|
-
|
|
Mar 01
2024
|
Cecilia Jones Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+11.42%
|
-
|
|
Mar 01
2024
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+12.79%
|
-
|
|
Mar 01
2024
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,834
+9.54%
|
-
|
|
Feb 27
2024
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
69,329
-20.34%
|
$2,357,186
$34.24 P/Share
|
|
Feb 27
2024
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
69,329
+16.13%
|
$2,149,199
$31.64 P/Share
|
|
Feb 26
2024
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
20,411
-14.25%
|
$673,563
$33.19 P/Share
|
|
Feb 26
2024
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,411
+12.47%
|
$632,741
$31.64 P/Share
|
|
Feb 23
2024
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
47,731
-27.98%
|
$1,575,123
$33.05 P/Share
|
|
Feb 23
2024
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
47,731
+21.86%
|
$1,479,661
$31.64 P/Share
|
|
Feb 20
2024
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
504
-15.53%
|
$13,104
$26.63 P/Share
|
|
Feb 14
2024
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
273
-7.76%
|
$6,825
$25.14 P/Share
|
|
Feb 14
2024
|
James William Burns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
545
-1.69%
|
$13,625
$25.14 P/Share
|
|
Feb 14
2024
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
642
-1.88%
|
$16,050
$25.14 P/Share
|
|
Feb 12
2024
|
Theodore James Washburn Jr. Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
777
+18.09%
|
-
|
|
Feb 12
2024
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,833
+5.38%
|
-
|
|
Feb 12
2024
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,162
+5.97%
|
-
|
|
Jan 24
2024
|
James William Burns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,708
-5.32%
|
$35,868
$21.64 P/Share
|
|
Jan 24
2024
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,635
-13.38%
|
$160,335
$21.64 P/Share
|
|
Jan 24
2024
|
Jacqualyn A Fouse Director |
SELL
Open market or private sale
|
Direct |
10,722
-7.66%
|
$225,162
$21.64 P/Share
|
|
Jan 24
2024
|
Cecilia Jones Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,886
-12.61%
|
$39,606
$21.64 P/Share
|
|
Jan 24
2024
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,708
-5.08%
|
$35,868
$21.64 P/Share
|
|
Jan 24
2024
|
Tsveta Milanova Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,618
-10.89%
|
$33,978
$21.64 P/Share
|
|
Jan 20
2024
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,750
+15.2%
|
-
|
|
Jan 20
2024
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,018
+22.97%
|
-
|
|
Jan 20
2024
|
Jacqualyn A Fouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
23,900
+14.58%
|
-
|
|
Jan 20
2024
|
Cecilia Jones Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,380
+26.46%
|
-
|
|
Jan 20
2024
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,750
+14.61%
|
-
|
|
Jan 20
2024
|
Tsveta Milanova Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,448
+26.84%
|
-
|
|
Jan 09
2024
|
James William Burns Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,163
-4.23%
|
$25,586
$22.99 P/Share
|
|
Jan 09
2024
|
Jacqualyn A Fouse Director |
SELL
Open market or private sale
|
Direct |
8,391
-6.74%
|
$184,602
$22.99 P/Share
|
|
Jan 09
2024
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,066
-23.15%
|
$265,452
$22.99 P/Share
|
|
Jan 09
2024
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,789
-6.03%
|
$39,358
$22.99 P/Share
|
|
Jan 05
2024
|
James William Burns Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,250
+10.57%
|
-
|
|
Jan 05
2024
|
Jacqualyn A Fouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+12.33%
|
-
|
|
Jan 05
2024
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,527
+32.88%
|
-
|
|
Jan 05
2024
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+14.43%
|
-
|
|
Jan 05
2024
|
Tsveta Milanova Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,902
-23.58%
|
$63,844
$22.32 P/Share
|
|
Jan 03
2024
|
Tsveta Milanova Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,475
+40.78%
|
-
|